Nicole White
Corporate Officer/Principal presso ASSEMBLY BIOSCIENCES, INC.
Patrimonio netto: 194 723 $ in data 31/05/2024
Posizioni attive di Nicole White
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Corporate Officer/Principal | 17/11/2020 | - |
Storia della carriera di Nicole White
Precedenti posizioni note di Nicole White
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GOSSAMER BIO, INC. | Corporate Officer/Principal | 01/05/2018 | 01/11/2020 |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/10/2015 | 01/04/2018 |
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01/03/2009 | 01/10/2015 |
Formazione di Nicole White
| University of California, Irvine | Doctorate Degree |
| University of California San Diego | Undergraduate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 7 |
Posizioni
| Corporate Officer/Principal | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Settori
| Health Technology | 5 |
| Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| ASSEMBLY BIOSCIENCES, INC. | Health Technology |
| GOSSAMER BIO, INC. | Health Technology |
| GILEAD SCIENCES, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
- Borsa valori
- Insiders
- Nicole White
- Esperienza
